PT-141 (Bremelanotide): The Complete Research Guide (2026)

PT-141 is one of a handful of peptides that crossed from preclinical research into FDA-approved therapeutic use - and it did so for a mechanism that most researchers didn't see coming. Originally developed as a tanning agent, bremelanotide ended up being approved for hypoactive sexual desire disorder (HSDD) after clinical trials revealed unexpected effects on sexual arousal pathways.

This guide covers what the published research actually shows, how PT-141 works at the receptor level, and what researchers should know about handling this compound.

What Is PT-141?

PT-141 (bremelanotide) is a cyclic heptapeptide - a seven-amino acid ring structure - that acts as a non-selective agonist at melanocortin receptors (MCRs). Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a molecular weight of approximately 1,025.18 Da.

It was derived from Melanotan II (MT-II) through structural modification. While MT-II acts on both melanocortin and other receptor systems, PT-141 was designed to retain melanocortin receptor activity while reducing off-target effects - though it still activates multiple MCR subtypes.

Key facts:

• Molecular formula: C₅₀H₆₈N₁₄O₁₀
• Molecular weight: ~1,025.18 Da
• Amino acid count: 7 (cyclic)
• Drug class: Melanocortin receptor agonist
• Brand name: Vyleesi (FDA-approved 2019)
• Bioavailability: ~100% (subcutaneous)
• Half-life: ~2.7 hours
• CAS Number: 189691-06-3

Important note for researchers: PT-141 is a scheduled prescription medication in many jurisdictions. Research-grade PT-141 is sold strictly for in vitro and preclinical research purposes. This guide covers the published scientific literature and does not constitute medical advice.

The Melanocortin System: Why It Matters

To understand PT-141, you need to understand the melanocortin system - one of the most underappreciated signaling networks in mammalian biology.

The Five Melanocortin Receptors

The melanocortin receptor family consists of five G-protein coupled receptors (MC1R through MC5R), each with distinct tissue distributions and functions:

PT-141 primarily exerts its effects through MC3R and MC4R activation in the central nervous system. This is what makes it fundamentally different from peripheral vasodilator compounds - it acts on brain circuits, not blood vessels.

Central vs. Peripheral Mechanism

This distinction matters. Most compounds that affect sexual function work peripherally - they increase blood flow through nitric oxide pathways or other vascular mechanisms. PT-141 works centrally, activating hypothalamic melanocortin circuits that modulate arousal and desire at the neurological level.

Published research has shown that MC4R activation in the paraventricular nucleus of the hypothalamus triggers downstream dopaminergic and oxytocinergic signaling. This is a fundamentally different pathway from phosphodiesterase inhibitors or other peripheral approaches.

From Melanotan to Bremelanotide: Development History

The Tanning Connection

The PT-141 story begins with alpha-melanocyte stimulating hormone (α-MSH), a naturally occurring peptide that stimulates melanin production. Researchers at the University of Arizona developed synthetic analogs of α-MSH in the 1980s and 1990s, leading to Melanotan I and Melanotan II.

Melanotan II (MT-II) was designed as a more potent tanning peptide, but clinical researchers noticed it produced spontaneous effects on sexual arousal - an unexpected finding that redirected the entire research program.

Designing PT-141

PT-141 was created by modifying MT-II to retain the sexual arousal effects while minimizing the tanning and appetite-suppressing effects. The key structural change was removing the linear C-terminal tail of MT-II and acetylating the N-terminus, creating a more targeted cyclic peptide.

Palatin Technologies developed bremelanotide through clinical trials, eventually receiving FDA approval in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Published Clinical Research

Phase III Trials (RECONNECT Studies)

The two pivotal Phase III trials - RECONNECT-1 and RECONNECT-2 - enrolled over 1,200 premenopausal women with HSDD. Key findings from the published data:

• Primary endpoint: Statistically significant increase in satisfying sexual events (SSEs) vs. placebo
• Secondary endpoints: Significant improvement in sexual desire scores (Female Sexual Function Index - desire domain) and reduction in distress scores (Female Sexual Distress Scale)
• Dose: 1.75 mg subcutaneous, administered at least 45 minutes before anticipated activity
• Duration: 24 weeks of treatment

The effect sizes were modest but statistically significant. Researchers have noted that the clinical meaningfulness of these effect sizes continues to be debated in the literature.

Side Effect Profile (Published Data)

From the clinical trial data and FDA label:

• Nausea: ~40% of participants (most common; often decreases with subsequent doses)
• Flushing: ~20%
• Injection site reactions: ~13%
• Headache: ~11%
• Transient hypertension: Observed in clinical trials; blood pressure typically returned to baseline within 12 hours
• Hyperpigmentation: Reported in some participants, particularly gums, face, and breasts - consistent with melanocortin activation

Cardiovascular Considerations

PT-141 produces a transient increase in blood pressure and decrease in heart rate. The FDA label specifically warns against use in patients with uncontrolled hypertension or cardiovascular disease. This cardiovascular effect is consistent with central melanocortin activation affecting autonomic regulation.

Receptor Pharmacology: The Details

Binding Affinity Profile

Published binding studies show PT-141 has the following approximate affinity profile:

• MC4R: High affinity (Ki in low nanomolar range)
• MC3R: Moderate-to-high affinity
• MC1R: Moderate affinity (explains residual pigmentation effects)
• MC5R: Lower affinity
• MC2R: Minimal activity

The MC4R selectivity over MC1R is better than MT-II but not absolute. This is why some pigmentation effects persist even with the structural modifications.

Signaling Cascade

When PT-141 binds MC4R in hypothalamic neurons, the published signaling cascade involves:

1. G-protein activation: Gαs coupling leads to adenylyl cyclase activation and cAMP production
2. Downstream signaling: Activation of PKA and CREB transcription factor phosphorylation
3. Neurotransmitter release: Enhanced dopamine release in the medial preoptic area
4. Oxytocin pathway: Activation of oxytocinergic neurons in the paraventricular nucleus
5. Spinal cord circuits: Descending signals modulate peripheral autonomic responses

This multi-step central mechanism explains why the onset of action (45+ minutes) is slower than peripheral vasodilators.

Research Directions Beyond HSDD

Male Sexual Dysfunction Studies

Earlier phase clinical trials investigated PT-141 in male erectile dysfunction. Published results showed efficacy in some men who didn't respond to PDE5 inhibitors, suggesting the central mechanism could complement peripheral approaches. However, Palatin Technologies pursued the female HSDD indication for regulatory strategy reasons, and male indications have not been pursued to approval.

Hemorrhagic Shock Research

Interestingly, melanocortin receptor agonists including PT-141-related compounds have been investigated in hemorrhagic shock models. Published preclinical research suggests MC3R/MC4R activation may have protective effects during ischemia-reperfusion, potentially through anti-inflammatory signaling cascades.

Appetite and Metabolic Research

MC4R is a critical node in appetite regulation. While PT-141 was optimized away from appetite effects, the melanocortin system's role in obesity research remains an active area. Other MC4R agonists (setmelanotide) have been approved for rare genetic obesity conditions.

Neuroinflammation

Emerging preclinical research suggests melanocortin signaling may modulate neuroinflammatory processes. MC4R activation has been linked to reduced microglial activation in animal models, though this research is early-stage and far from clinical application.

Handling and Reconstitution for Research

Lyophilized Form

Research-grade PT-141 typically comes as a white lyophilized powder. Key handling considerations:

• Storage (lyophilized): -20°C or lower, protected from light and moisture
• Reconstitution solvent: Bacteriostatic water (0.9% benzyl alcohol) is standard for research use
• Reconstituted stability: Use within 14-28 days when stored at 2-8°C; stability degrades faster at room temperature
• Avoid: Repeated freeze-thaw cycles, prolonged light exposure

Reconstitution Protocol

For researchers new to peptide handling, refer to our detailed guide: How to Reconstitute Peptides: Complete Guide.

Standard reconstitution for PT-141:

1. Allow the vial to reach room temperature (10-15 minutes)
2. Add bacteriostatic water slowly along the vial wall - do not inject directly onto the powder
3. Gently swirl (never shake) until fully dissolved
4. The solution should be clear and colorless - discard if cloudy or particulate
5. Store reconstituted solution at 2-8°C, protected from light

Purity Verification

Always verify peptide purity through Certificate of Analysis (CoA). For guidance on reading CoAs, see: How to Read a Peptide CoA.

Key quality markers for PT-141:

• HPLC purity: average 99.7%
• Mass spectrometry: Confirmed molecular weight of 1,025.18 Da
• Endotoxin levels: <5 EU/mg (particularly important for in vivo research)
• Residual solvent testing: Below ICH Q3C limits

PT-141 vs. Related Compounds

PT-141 vs. Melanotan II

Both are melanocortin agonists, but with important differences:

• Selectivity: PT-141 has somewhat better MC4R selectivity; MT-II is more broadly active across all MCR subtypes
• Pigmentation: MT-II causes significantly more tanning; PT-141 has reduced but not eliminated pigmentation effects
• Structure: PT-141 is a cyclic heptapeptide; MT-II is a linear-cyclic hybrid
• Regulatory status: PT-141 (as bremelanotide/Vyleesi) is FDA-approved; MT-II has no regulatory approval anywhere

PT-141 vs. Setmelanotide (Imcivree)

Setmelanotide is another MC4R agonist, but optimized for appetite regulation in rare genetic obesity conditions (POMC, PCSK1, LEPR deficiency). While both target MC4R, their clinical profiles differ significantly due to dosing strategies, selectivity profiles, and target populations.

PT-141 in the Broader Peptide Landscape

For researchers exploring the peptide research space, our overview covers the most studied compounds: Best Research Peptides for 2026. PT-141 occupies a unique niche as one of the few centrally-acting peptides with full FDA clinical trial data available for review.

Proper Storage for Long-Term Research

Peptide degradation is a real concern that can compromise research results. For comprehensive storage protocols applicable to PT-141 and other research peptides, see our Peptide Storage Guide.

PT-141-specific storage notes:

• Cyclic peptides generally have better stability than linear peptides due to reduced enzymatic attack surfaces
• The acetylated N-terminus provides additional protection against aminopeptidases
• Despite this, reconstituted solutions should not be kept beyond 28 days even under optimal conditions
• For long-term storage of lyophilized powder, desiccant packets in the storage container are recommended

Key Takeaways for Researchers

1. Central mechanism: PT-141 works through hypothalamic melanocortin circuits, not peripheral vascular pathways - this is fundamentally different from most compounds in its therapeutic space.

2. FDA data available: Unlike most research peptides, PT-141 has extensive published Phase III clinical trial data, making it one of the best-characterized peptides for researchers to study.

3. Multi-receptor activity: Despite optimization, PT-141 retains activity at MC1R (pigmentation) and MC3R (metabolic), not just MC4R. Researchers should account for this in experimental design.

4. Cardiovascular effects: The transient blood pressure increase is well-documented and should be considered in any research protocol design.

5. Nausea signal: The 40% nausea incidence in clinical trials is notable and likely related to central melanocortin activation in brainstem circuits (area postrema).

6. Emerging applications: Research beyond sexual function - including hemorrhagic shock, neuroinflammation, and metabolic regulation - represents active frontiers for melanocortin pharmacology.

The Bottom Line

PT-141 represents a genuinely novel mechanism in peptide pharmacology. Its journey from tanning peptide derivative to FDA-approved therapeutic illustrates how biological systems rarely do just one thing - melanocortin receptors in the hypothalamus turned out to be far more interesting than melanocortin receptors in the skin.

For researchers, PT-141 offers the unusual advantage of extensive published clinical data to inform experimental design. The melanocortin system itself remains an active area of investigation with potential applications well beyond the current approved indication. For a detailed breakdown of how PT-141 stacks up against Melanotan II, Kisspeptin-10, and oxytocin, see our PT-141 vs Other Peptides comparison.

Vantage Peptide provides research-grade peptides with comprehensive Certificates of Analysis. All products are for research use only. Browse our full product catalog for available compounds.